<p>马丁库里有限公司在最近向证券交易委员会提交的文件中表示，在第二季度将其在礼来公司（NYSE:LLY - 免费报告）的持股减少了 0.9%。该基金在此期间出售了 298 股后，持有该公司 34,544 股股票。礼来公司约占马丁库里有限公司投资组合的 1.0%，使其成为该公司第 29 大持股。截至最近的 SEC 文件，马丁库里有限公司在礼来公司的持股价值为 26,928,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>一项宏伟的人工智能投资？斯坦利·德鲁肯米勒最新的科技动态</li>
</ul>
<p>其他一些大型投资者最近也调整了他们在 LLY 的持股。Braun Bostich &amp; Associates Inc.在第二季度将其在礼来公司的股份增加了 2.5%。Braun Bostich &amp; Associates Inc.现在持有 527 股该公司的股票，价值 411,000 美元，此前在上个季度又购买了 13 股。Rise Advisors LLC 在第二季度将其在礼来公司的股份增加了 1.8%。Rise Advisors LLC 现在持有 732 股该公司的股票，价值 571,000 美元，此前在上个季度又购买了 13 股。Occidental Asset Management LLC 在第二季度将其在礼来公司的持股增加了 0.7%。Occidental Asset Management LLC 现在持有 1,966 股该公司的股票，价值 1,533,000 美元，此前在此期间又购买了 13 股。New Insight Wealth Advisors 在第二季度将其在礼来公司的持股增加了 3.4%。New Insight Wealth Advisors 现在持有 394 股该公司的股票，价值 307,000 美元，此前在此期间又购买了 13 股。最后，Dash Acquisitions Inc.在第二季度将其在礼来公司的持股增加了 2.8%。Dash Acquisitions Inc.现在持有 485 股该公司的股票，价值 387,000 美元，此前在上个季度又购买了 13 股。目前 82.53% 的股票由机构投资者和对冲基金持有。</p>
<h2>礼来公司股价下跌 0.6%</h2>
<p>礼来公司的股票在周五开盘价为 1,042.86 美元。该公司的 50 日移动平均线为 849.83 美元，200 日移动平均线为 786.02 美元。该股票的市值为 9859 亿美元，市盈率为 68.16，市盈增长比率为 1.21，贝塔值为 0.43。礼来公司的 52 周低点为 623.78 美元，52 周高点为 1,057.00 美元。该公司的债务与股本比率为 1.86，速动比率为 1.00，流动比率为 1.28。</p>
<ul>
<li>HIMS 经历了过山车般的旅程。投资者应该加入吗？</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近于 10 月 30 日发布了季度财报。该公司报告季度每股收益为 7.02 美元，超出分析师一致预期的 6.42 美元，超出幅度为 0.60 美元。该公司季度收入为 176 亿美元，而分析师预期为 160.9 亿美元。礼来公司的净利润率为 25.91%，股本回报率为 92.72%。与去年同期相比，礼来公司的季度收入增长了 53.9%。去年同期，该公司每股收益为 1.18 美元。礼来公司已将 2025 财年的指导目标设定为 23.000-23.700 每股收益。整体来看，卖方分析师预测礼来公司今年将发布 23.48 每股收益。</p>
<h2>礼来公司宣布分红</h2>
<p>该公司最近还宣布了一项季度分红，将于 12 月 10 日（星期三）支付。11 月 14 日（星期五）的股东将获得 1.50 美元的分红。这相当于年化 6.00 美元的分红，分红收益率为 0.6%。除息日为 11 月 14 日（星期五）。礼来公司的派息比率目前为 29.35%。</p>
<h2>分析师设定新的价格目标</h2>
<ul>
<li>年初至今下跌 45%，诺和诺德引发价格战</li>
</ul>
<p>几位研究分析师最近对该公司发表了评论。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对礼来公司股票的 “持有（c+）” 评级。Loop Capital 在 11 月 10 日（星期一）的研究报告中对礼来公司的股票设定了 950.00 美元的目标价。摩根士丹利在 11 月 13 日（星期四）将礼来公司的股票目标价从 1,090.00 美元上调至 1,171.00 美元，并给予该公司 “增持” 评级。加拿大丰业银行在 11 月 13 日（星期四）的研究报告中对礼来公司的股票进行了覆盖，设定了 “行业表现优于大盘” 的评级和 1,165.00 美元的目标价。最后，Berenberg Bank 在 9 月 17 日（星期三）的研究报告中重申了 “持有” 评级，并对礼来公司的股票设定了 830.00 美元的目标价（之前为 970.00 美元）。三位投资分析师对该股票给予了强烈买入评级，十五位给予了买入评级，七位给予了持有评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 1,027.95 美元。</p>
<p><strong>查看我们最新的 LLY 股票报告</strong></p>
<h2>关于礼来公司</h2>
<p>（免费报告）</p>
<p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>多伦多证券交易所创业板（前称加拿大创业交易所）</li>
<li>Datavault AI 刚刚将指引上调了 400%——你在关注吗？</li>
<li>如何一步一步购买便宜股票</li>
<li>彼得·蒂尔抛售 NVIDIA 并削减特斯拉股份——人工智能泡沫即将破裂吗？</li>
<li>如何有效使用 MarketBeat 评级筛选器</li>
<li>为什么锂美洲可能是 2030 年的强劲投资——而不是 2025 年的</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元于礼来公司吗？</h2>
<p>在考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>马丁库里有限公司在第二季度将其在礼来的股份减少了 0.9%，目前持有 34,544 股，价值 2693 万美元。礼来股票占马丁库里投资组合的 1%。其他投资者也调整了他们的持股。礼来报告第三季度每股收益为 7.02 美元，超出预期，营收同比增长 53.9%。该公司宣布季度股息为每股 1.50 美元，将于 12 月 10 日支付</p>

<p>Martin Currie Ltd. reduced its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 0.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 34,544 shares of the company's stock after selling 298 shares during the period. Eli Lilly and Company accounts for about 1.0% of Martin Currie Ltd.'s portfolio, making the stock its 29th largest holding. Martin Currie Ltd.'s holdings in Eli Lilly and Company were worth $26,928,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>马丁库里有限公司在最近向证券交易委员会提交的文件中表示，在第二季度将其在礼来公司（NYSE:LLY - 免费报告）的持股减少了 0.9%。该基金在此期间出售了 298 股后，持有该公司 34,544 股股票。礼来公司约占马丁库里有限公司投资组合的 1.0%，使其成为该公司第 29 大持股。截至最近的 SEC 文件，马丁库里有限公司在礼来公司的持股价值为 26,928,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
</ul>
<div class="lb-trans"><ul>
<li>一项宏伟的人工智能投资？斯坦利·德鲁肯米勒最新的科技动态</li>
</ul>
</div><p>A number of other large investors also recently modified their holdings of LLY. Braun Bostich &amp; Associates Inc. grew its stake in shares of Eli Lilly and Company by 2.5% in the second quarter. Braun Bostich &amp; Associates Inc. now owns 527 shares of the company's stock valued at $411,000 after buying an additional 13 shares in the last quarter. Rise Advisors LLC increased its stake in shares of Eli Lilly and Company by 1.8% during the 2nd quarter. Rise Advisors LLC now owns 732 shares of the company's stock worth $571,000 after purchasing an additional 13 shares during the last quarter. Occidental Asset Management LLC raised its holdings in shares of Eli Lilly and Company by 0.7% in the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company's stock valued at $1,533,000 after purchasing an additional 13 shares during the period. New Insight Wealth Advisors grew its holdings in Eli Lilly and Company by 3.4% during the second quarter. New Insight Wealth Advisors now owns 394 shares of the company's stock worth $307,000 after purchasing an additional 13 shares during the period. Finally, Dash Acquisitions Inc. increased its position in Eli Lilly and Company by 2.8% during the second quarter. Dash Acquisitions Inc. now owns 485 shares of the company's stock worth $387,000 after buying an additional 13 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些大型投资者最近也调整了他们在 LLY 的持股。Braun Bostich &amp; Associates Inc.在第二季度将其在礼来公司的股份增加了 2.5%。Braun Bostich &amp; Associates Inc.现在持有 527 股该公司的股票，价值 411,000 美元，此前在上个季度又购买了 13 股。Rise Advisors LLC 在第二季度将其在礼来公司的股份增加了 1.8%。Rise Advisors LLC 现在持有 732 股该公司的股票，价值 571,000 美元，此前在上个季度又购买了 13 股。Occidental Asset Management LLC 在第二季度将其在礼来公司的持股增加了 0.7%。Occidental Asset Management LLC 现在持有 1,966 股该公司的股票，价值 1,533,000 美元，此前在此期间又购买了 13 股。New Insight Wealth Advisors 在第二季度将其在礼来公司的持股增加了 3.4%。New Insight Wealth Advisors 现在持有 394 股该公司的股票，价值 307,000 美元，此前在此期间又购买了 13 股。最后，Dash Acquisitions Inc.在第二季度将其在礼来公司的持股增加了 2.8%。Dash Acquisitions Inc.现在持有 485 股该公司的股票，价值 387,000 美元，此前在上个季度又购买了 13 股。目前 82.53% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Eli Lilly and Company Trading Down 0.6%</h2>
<div class="lb-trans"><h2>礼来公司股价下跌 0.6%</h2>
</div><p>Shares of Eli Lilly and Company stock opened at $1,042.86 on Friday. The firm has a 50-day moving average of $849.83 and a 200-day moving average of $786.02. The stock has a market cap of $985.90 billion, a PE ratio of 68.16, a PEG ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,057.00. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.</p>
<div class="lb-trans"><p>礼来公司的股票在周五开盘价为 1,042.86 美元。该公司的 50 日移动平均线为 849.83 美元，200 日移动平均线为 786.02 美元。该股票的市值为 9859 亿美元，市盈率为 68.16，市盈增长比率为 1.21，贝塔值为 0.43。礼来公司的 52 周低点为 623.78 美元，52 周高点为 1,057.00 美元。该公司的债务与股本比率为 1.86，速动比率为 1.00，流动比率为 1.28。</p>
</div><ul>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
</ul>
<div class="lb-trans"><ul>
<li>HIMS 经历了过山车般的旅程。投资者应该加入吗？</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts' consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period last year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近于 10 月 30 日发布了季度财报。该公司报告季度每股收益为 7.02 美元，超出分析师一致预期的 6.42 美元，超出幅度为 0.60 美元。该公司季度收入为 176 亿美元，而分析师预期为 160.9 亿美元。礼来公司的净利润率为 25.91%，股本回报率为 92.72%。与去年同期相比，礼来公司的季度收入增长了 53.9%。去年同期，该公司每股收益为 1.18 美元。礼来公司已将 2025 财年的指导目标设定为 23.000-23.700 每股收益。整体来看，卖方分析师预测礼来公司今年将发布 23.48 每股收益。</p>
</div><h2>Eli Lilly and Company Announces Dividend</h2>
<div class="lb-trans"><h2>礼来公司宣布分红</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company's payout ratio is presently 29.35%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 12 月 10 日（星期三）支付。11 月 14 日（星期五）的股东将获得 1.50 美元的分红。这相当于年化 6.00 美元的分红，分红收益率为 0.6%。除息日为 11 月 14 日（星期五）。礼来公司的派息比率目前为 29.35%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><ul>
<li>Down 45% Year-to-Date, Novo Nordisk Ignites a Price War</li>
</ul>
<div class="lb-trans"><ul>
<li>年初至今下跌 45%，诺和诺德引发价格战</li>
</ul>
</div><p>Several research analysts have recently commented on the company. Weiss Ratings reiterated a &#34;hold (c+)&#34; rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. Loop Capital set a $950.00 price objective on shares of Eli Lilly and Company in a research report on Monday, November 10th. Morgan Stanley upped their price objective on shares of Eli Lilly and Company from $1,090.00 to $1,171.00 and gave the company an &#34;overweight&#34; rating in a report on Thursday, November 13th. Scotiabank assumed coverage on shares of Eli Lilly and Company in a research note on Thursday, November 13th. They set a &#34;sector outperform&#34; rating and a $1,165.00 target price for the company. Finally, Berenberg Bank reiterated a &#34;hold&#34; rating and issued a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $1,027.95.</p>
<div class="lb-trans"><p>几位研究分析师最近对该公司发表了评论。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对礼来公司股票的 “持有（c+）” 评级。Loop Capital 在 11 月 10 日（星期一）的研究报告中对礼来公司的股票设定了 950.00 美元的目标价。摩根士丹利在 11 月 13 日（星期四）将礼来公司的股票目标价从 1,090.00 美元上调至 1,171.00 美元，并给予该公司 “增持” 评级。加拿大丰业银行在 11 月 13 日（星期四）的研究报告中对礼来公司的股票进行了覆盖，设定了 “行业表现优于大盘” 的评级和 1,165.00 美元的目标价。最后，Berenberg Bank 在 9 月 17 日（星期三）的研究报告中重申了 “持有” 评级，并对礼来公司的股票设定了 830.00 美元的目标价（之前为 970.00 美元）。三位投资分析师对该股票给予了强烈买入评级，十五位给予了买入评级，七位给予了持有评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 1,027.95 美元。</p>
</div><p><strong>View Our Latest Stock Report on LLY</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 LLY 股票报告</strong></p>
</div><h2>About Eli Lilly and Company</h2>
<div class="lb-trans"><h2>关于礼来公司</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li>
<li>Datavault AI Just Raised Guidance by 400%—Are You Paying Attention?</li>
<li>How to Buy Cheap Stocks Step by Step</li>
<li>Peter Thiel Dumps NVIDIA and Slashes Tesla Stake—Is the AI Bubble About to Pop?</li>
<li>How to Effectively Use the MarketBeat Ratings Screener</li>
<li>Why Lithium Americas Could Be a 2030 Power Play—Not a 2025 One</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>多伦多证券交易所创业板（前称加拿大创业交易所）</li>
<li>Datavault AI 刚刚将指引上调了 400%——你在关注吗？</li>
<li>如何一步一步购买便宜股票</li>
<li>彼得·蒂尔抛售 NVIDIA 并削减特斯拉股份——人工智能泡沫即将破裂吗？</li>
<li>如何有效使用 MarketBeat 评级筛选器</li>
<li>为什么锂美洲可能是 2030 年的强劲投资——而不是 2025 年的</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Martin Currie Ltd. 持有礼来公司价值 2693 万美元的股份